Home

Articles from Mind Medicine

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Mind Medicine (MindMed) Inc. (NASDAQMNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking place December 8 – 11 in Phoenix, AZ.
By Mind Medicine · Via Business Wire · December 11, 2024
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
Mind Medicine (MindMed) Inc. (NASDAQMNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.
By Mind Medicine · Via Business Wire · June 20, 2024
MindMed to Present at Upcoming April Medical Conferences
Mind Medicine (MindMed) Inc. (NASDAQMNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:
By Mind Medicine · Via Business Wire · April 2, 2024
MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate) in generalized anxiety disorder (GAD). The trial met its primary endpoint, with MM-120 demonstrating statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety rating scale (HAM-A) compared to placebo at Week 4. MM-120 was administered as a single-dose in a monitored clinical setting with no additional therapeutic intervention.
By Mind Medicine · Via Business Wire · December 14, 2023
MindMed Reports Third Quarter 2023 Financial Results and Business Highlights
Mind Medicine (MindMed) Inc. (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.
By Mind Medicine · Via Business Wire · November 2, 2023
MindMed Announces Election of All Six Company Nominees at Annual Meeting
Mind Medicine (MindMed) Inc. (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that, based upon a preliminary vote assessment, shareholders have elected all six of the Company’s nominees – CEO Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs and Carol A. Vallone – to the Board of Directors (the “Board”) at the Annual Meeting of Shareholders (the "Meeting") held today.
By Mind Medicine · Via Business Wire · June 21, 2023
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
Mind Medicine (MindMed) Inc (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, will provide an overview of clinical progress and corporate updates during an Investor Day today focused primarily on the MM-120 (lysergide D-tartrate) program in generalized anxiety disorder (GAD).
By Mind Medicine · Via Business Wire · June 20, 2023
MindMed Adjourns Annual General Meeting of Shareholders
Mind Medicine (MindMed) Inc. (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), today announced that the Company’s Annual General Meeting of Shareholders (the “Meeting”) on June 15, 2023 was convened at 10:00 a.m. (Eastern Time) and adjourned, without any business being conducted, due to lack of the required quorum. The Meeting will resume with respect to all proposals at 10:00 a.m. (Eastern Time) on Wednesday, June 21, 2023 and will continue to be held virtually via live webcast at www.proxydocs.com/MNMD.
By Mind Medicine · Via Business Wire · June 15, 2023
MindMed to Host Investor Day June 2023
Mind Medicine (MindMed) Inc (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that its management team will a host an Analyst Day in New York City on Tuesday, June 20th, 2023 that will focus on the MM-120 program in generalized anxiety disorder (GAD). In person attendance is by invitation only. All others are invited to participate via the live webcast.
By Mind Medicine · Via Business Wire · June 7, 2023
MindMed to Participate at Upcoming Investor Conferences
Mind Medicine (MindMed) Inc (NASDAQMNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
By Mind Medicine · Via Business Wire · June 1, 2023